# EDGAR Filing Document

**Accession Number:** 0001831363
**File Stem:** 0001213900-23-008397
**Filing Date:** 2023-2
**Character Count:** 19804
**Document Hash:** 04269777cff384d66c2926799efb2255
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-008397.hdr.sgml**: 20230206

**ACCESSION NUMBER**: 0001213900-23-008397

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230206

**DATE AS OF CHANGE**: 20230206

**GROUP MEMBERS**: HOPEWELL RESOURCES HOLDINGS LTD

**GROUP MEMBERS**: LAV AQUA LTD

**GROUP MEMBERS**: ORIENTAL SPRING VENTURE LTD

**GROUP MEMBERS**: YI SHI

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Terns Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001831363
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92116
- **FILM NUMBER:** 23590037

**BUSINESS ADDRESS:**
- **STREET 1:** 1065 EAST HILLSDALE BLVD., SUITE 100
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 650-525-5535 EXT.101

**MAIL ADDRESS:**
- **STREET 1:** 1065 EAST HILLSDALE BLVD., SUITE 100
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LAV Biosciences Fund V, L.P.
- **CENTRAL INDEX KEY:** 0001764435
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** C/O ESTERA TRUST (CAYMAN) LIMITED
- **STREET 2:** 75 FORT STREET, PO BOX 1350
- **CITY:** GRAND CAYMAN
- **STATE:** E9
- **ZIP:** KY1-1108
- **BUSINESS PHONE:** 345-640-0540

**MAIL ADDRESS:**
- **STREET 1:** C/O ESTERA TRUST (CAYMAN) LIMITED
- **STREET 2:** 75 FORT STREET, PO BOX 1350
- **CITY:** GRAND CAYMAN
- **STATE:** E9
- **ZIP:** KY1-1108

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 2)\***

**Terns Pharmaceuticals, Inc.**

(Name of Issuer)

**Common Stock, $0.0001 par value per share**

(Title of Class of Securities)

**880881107**

(CUSIP Number)

**December 31, 2022**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

&nbsp;&nbsp;&nbsp;&nbsp;☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 2 of 11 |

---

1. Name
of Reporting Person **Hopewell Resources Holdings Limited ("HOPE")** 

2. Check
the Appropriate Box if a Member of a Group (see instructions) (a) ☐ (b) ☒

3. SEC
 USE ONLY

4. Citizenship
or Place of Organization British
 Virgin Islands

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;5. | &nbsp;&nbsp;Sole Voting Power<br>**919,523 shares, except that Yi Shi, the managing partner of HOPE, may be deemed to have shared power to vote these shares.**<br>|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;6. | &nbsp;&nbsp;Shared Voting Power<br>**See response to row 5.** |
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;7. | &nbsp;&nbsp;Sole Dispositive Power<br>**919,523 shares, except that Yi Shi, the managing partner of HOPE, may be deemed to have shared power to dispose of these shares.**<br>|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;8. | &nbsp;&nbsp;Shared Dispositive Power<br>**See response to row 7.** |

---

9. Aggregate
Amount Beneficially Owned by Each Reporting Person **919,523** 

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

11. Percent
of Class Represented by Amount in Row 9 **1.9%(1)** 

12. Type
of Reporting Person (see instructions) **OO** 

(1) This percentage is calculated based upon 47,963,829 shares of
common stock outstanding of Terns Pharmaceuticals, Inc. (the **"Issuer"**), as set forth in the Issuer's Prospectus
Supplement dated December 20, 2022 filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended, filed with the SEC on
December 21, 2022.

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 3 of 11 |

---

1. Name
of Reporting Person **Oriental Spring Venture Limited ("ORIEN")** 

2. Check
the Appropriate Box if a Member of a Group (see instructions) (a) ☐ (b) ☒

3. SEC
 USE ONLY

4. Citizenship
or Place of Organization **British Virgin Islands** 

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;5. | &nbsp;&nbsp;Sole Voting Power<br>**459,762 shares, except that Yi Shi, the managing partner of ORIEN, may be deemed to have shared power to vote these shares.**<br>|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;6. | &nbsp;&nbsp;Shared Voting Power<br>**See response to Row 5.** |
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;7. | &nbsp;&nbsp;Sole Dispositive Power<br>**459,762 shares, except that Yi Shi, the managing partner of ORIEN, may be deemed to have shared power to dispose of these shares.**<br>|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;8. | &nbsp;&nbsp;Shared Dispositive Power<br>**See response to Row 7.** |

---

9. Aggregate
Amount Beneficially Owned by Each Reporting Person **459,762** 

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

11. Percent
of Class Represented by Amount in Row 9 **1.0%(1)** 

12. Type
of Reporting Person (see instructions) **OO** 

(1) This percentage is calculated based upon 47,963,829 shares of
common stock outstanding of Terns Pharmaceuticals, Inc. (the **"Issuer"**), as set forth in the Issuer's Prospectus
Supplement dated December 20, 2022 filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended, filed with the SEC on
December 21, 2022.

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 4 of 11 |

---

1. Name
of Reporting Person **LAV Aqua Limited ("AQUA")** 

2. Check
the Appropriate Box if a Member of a Group (see instructions) (a) ☐ (b) ☒

3. SEC
 USE ONLY

4. Citizenship
or Place of Organization **British Virgin Islands** 

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;5. | &nbsp;&nbsp;Sole Voting Power<br>**1,136,698 shares, except that Yi Shi, the managing partner of AQUA, may be deemed to have shared power to vote these shares.** |
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;6. | &nbsp;&nbsp;Shared Voting Power<br>**See response to Row 5.** |
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;7. | &nbsp;&nbsp;Sole Dispositive Power<br>**1,136,698 shares, except that Yi Shi, the managing partner of AQUA, may be deemed to have shared power to dispose of these shares.** |
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;8. | &nbsp;&nbsp;Shared Dispositive Power<br>**See response to Row 7.** |

---

9. Aggregate
Amount Beneficially Owned by Each Reporting Person **1,136,698** 

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

11. Percent
of Class Represented by Amount in Row 9 **2.4%(1)** 

12. Type
of Reporting Person (see instructions) **OO** 

(1) This percentage is calculated based upon 47,963,829 shares of
common stock outstanding of Terns Pharmaceuticals, Inc. (the **"Issuer"**), as set forth in the Issuer's Prospectus
Supplement dated December 20, 2022 filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended, filed with the SEC on
December 21, 2022.

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 5 of 11 |

---

1. Name
of Reporting Person **LAV Biosciences Fund V, L.P. ("LAVV")** 

2. Check
the Appropriate Box if a Member of a Group (see instructions) (a) ☐ (b) ☒

3. SEC
 USE ONLY

4. Citizenship
or Place of Organization **Cayman Islands** 

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;5. | &nbsp;&nbsp;Sole Voting Power<br>**385,583 shares, except that Yi Shi, the managing partner of LAVV, may be deemed to have shared power to vote these shares.**<br>|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;6. | &nbsp;&nbsp;Shared Voting Power<br>**See response to row 5.** |
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;7. | &nbsp;&nbsp;Sole Dispositive Power<br>**385,583 shares, except that Yi Shi, the managing partner of LAVV, may be deemed to have shared power to dispose of these shares.**<br>|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;8. | &nbsp;&nbsp;Shared Dispositive Power<br>**See response to row 7.** |

---

9. Aggregate
Amount Beneficially Owned by Each Reporting Person **385,583** 

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

11. Percent
of Class Represented by Amount in Row 9 **0.8%(1)** 

12. Type
of Reporting Person (see instructions) **PN** 

(1) This percentage is calculated based upon 47,963,829 shares of
common stock outstanding of Terns Pharmaceuticals, Inc. (the **"Issuer"**), as set forth in the Issuer's Prospectus
Supplement dated December 20, 2022 filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended, filed with the SEC on
December 21, 2022.

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 6 of 11 |

---

1. Name
of Reporting Person **Yi Shi** 

2. Check
the Appropriate Box if a Member of a Group (see instructions) (c) ☐ (d) ☒

3. SEC
 USE ONLY

4. Citizenship
or Place of Organization **United States** 

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;5. | &nbsp;&nbsp;Sole Voting Power<br>**0**<br>|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;6. | &nbsp;&nbsp;Shared Voting Power<br>**2,901,566 shares, 919,523 of which are directly owned by HOPE, 459,762 of which are directly owned by ORIEN, 1,136,698 of which are directly owned by AQUA, and 385,583 of which are directly owned by LAVV. Yi Shi, the managing partner of HOPE, ORIEN, AQUA and LAVV, may be deemed to have shared power to vote these shares.** |
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;7. | &nbsp;&nbsp;Sole Dispositive Power<br>**0**<br>|
| &nbsp;&nbsp;Number of <br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting <br> Person<br> With: | &nbsp;&nbsp;8. | &nbsp;&nbsp;Shared Dispositive Power<br>**2,901,566 shares, 919,523 of which are directly owned by HOPE, 459,762 of which are directly owned by ORIEN, 1,136,698 of which are directly owned by AQUA, and 385,583 of which are directly owned by LAVV. Yi Shi, the managing partner of HOPE, ORIEN, AQUA and LAVV, may be deemed to have shared power to dispose of these shares.**  |

---

9. Aggregate
Amount Beneficially Owned by Each Reporting Person **2,901,566** 

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

11. Percent
of Class Represented by Amount in Row 9 **6.1%(1)** 

12. Type
of Reporting Person (see instructions) **IN** 

(1) This percentage is calculated based upon 47,963,829 shares of
common stock outstanding of Terns Pharmaceuticals, Inc. (the **"Issuer"**), as set forth in the Issuer's Prospectus
Supplement dated December 20, 2022 filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended, filed with the SEC on
December 21, 2022.

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 7 of 11 |

---

---

| | |
|:---|:---|
| **Item 1(a)** | **Name of Issuer.** |
|  | Terns Pharmaceuticals, Inc. (the "***Issuer***") |
| **Item 1(b)** | **Address of Issuer's Principal Executive Offices.** |
|  | 1065 East Hillsdale Blvd., Suite 100<br> Foster City, CA 94404 |
| **Item 2(a)** | **Name of Persons Filing.** |
|  | This Statement is filed by Hopewell Resources Holdings Limited ("HOPE"), Oriental Spring Venture Limited ("ORIEN"), LAV Aqua Limited ("AQUA"), LAV Biosciences Fund V, L.P. ("LAVV") and Dr. Yi Shi. The foregoing entities and individual are collectively referred to as the "Reporting Persons."<br>Dr. Shi is the managing partner of HOPE, ORIEN, AQUA and LAVV, and may be deemed to have shared power to vote and shared power to dispose of shares of the Issuer directly owned by HOPE, ORIEN, AQUA and LAVV. |
| **Item 2(b)** | **Address of Principal Business Office or, if none, Residence.** |
|  | The address for HOPE, ORIEN, AQUA, LAVV and Dr. Shi is Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong. |
| **Item 2(c)** | **Citizenship.** |
|  | HOPE, ORIEN and AQUA are British Virgin Islands business companies. LAVV is Cayman Islands partnership. Dr. Shi is a United States citizen. |
| **Item 2(d)** | **Title of Class of Securities.** |
|  | Common Stock, $0.0001 par value per share |
| **Item 2(e)** | **CUSIP Number.** |
|  | 880881107 |
| **Item 3** | **Not applicable.** |

---

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 8 of 11 |

---

Item 4. Ownership.

The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Persons is provided as of December 27, 2022:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** **Amount Beneficially Owned:** 

See Row 9 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Percent of Class:** 

See Row 11 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** **Number** **of shares as to which such person has:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole power to vote or to direct the vote:

See Row 5 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Shared power to vote or to direct the vote:

See Row 6 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Sole power to dispose or to direct the disposition of:

See Row 7 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for each Reporting Person.

Item 5. Ownership of 5 Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of a Group.

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 9 of 11 |

---

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | |
|:---|:---|
| Dated: February 6, 2023 | **HOPEWELL RESOURCES HOLDINGS LIMITED** |

---

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |
| Title: | Managing Partner |

---

---

| | |
|:---|:---|
| Dated: February 6, 2023 | **ORIENTAL SPRING VENTURE LIMITED** |

---

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |
| Title: | Managing Partner |

---

---

| | |
|:---|:---|
| Dated: February 6, 2023 | **LAV AQUA LIMITED** |

---

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |
| Title: | Managing Partner |

---

---

| | |
|:---|:---|
| Dated: February 6, 2023 | **LAV BIOSCIENCES FUND V, L.P.** |

---

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |
| Title: | Managing Partner |

---

---

| | |
|:---|:---|
| Dated: February 6, 2023 | **YI SHI** |

---

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |

---

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 10 of 11 |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Found on Sequentially Numbered Page** |
| [Exhibit A: Agreement of Joint Filing](#a_001) | 11 |

---

---

| | |
|:---|:---|
| **CUSIP No. 880881107** | Page 11 of 11 |

---

**EXHIBIT A**

**AGREEMENT OF JOINT FILING**

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of Terns Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

---

| | |
|:---|:---|
| Dated: February 6, 2023 | **HOPEWELL RESOURCES HOLDINGS LIMITED** |

---

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |
| Title: | Managing Partner |

---

**ORIENTAL SPRING VENTURE LIMITED**

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |
| Title: | Managing Partner |

---

**LAV AQUA LIMITED**

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |
| Title: | Managing Partner |

---

**LAV BIOSCIENCES FUND V, L.P.**

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |
| Title: | Managing Partner |

---

**YI SHI**

---

| | |
|:---|:---|
| By: | /s/ Yi Shi |
| Name: | Yi Shi |

---